Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Heartlink's laboratory and animal studies of proprietary synthetic compounds, based on the isoflavone structure, have provided valuable pre-clinical data at low dosage levels that may prove a useful source for the development of anti-cancer medicines.
Subscribe to our email newsletter
The drug screen study was designed to assess the anti-cancer activity of the selected compounds using a standard cell proliferation assay procedure, against nine human cancer cell lines.
The data showed the anti-proliferative and cytotoxic effects against a range of tumour cell lines following treatment with three of the company’s proprietary compounds.
The data also showed a positive outcome of a in-vivo study which was designed to test the effectiveness of two test compounds against tumours.
Heartlink CEO Tracey-Anne Dickens said data collected provides a basis on which to further develop the proprietary compounds and to seek alliances for research and development or commercialisation.